| Prev Close | 6.34 |
| Open | 6.35 |
| Day Low/High | 6.15 / 6.66 |
| 52 Wk Low/High | 4.95 / 12.73 |
| Volume | 303.87K |
| Exchange | NASDAQ |
| Shares Outstanding | 34.39M |
| Market Cap | 233.88M |
| Div & Yield | N.A. (N.A) |
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative ophthalmology, announced today that Phase 1/2 clinical data published online in The Lancet demonstrate positive long-term...
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that it has completed a 1:100 reverse split of its common stock.
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today will host a conference call on Monday, August 11, 2014 at 5:00 p.
Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital...
Advanced Cell Technology, Inc. (“ACT”) (OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that Paul K.
Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Paul Wotton, Ph.
Advanced Cell Technology, Inc. (“ACT” or “the Company”; OTC:ACTC), a leader in the field of regenerative medicine, announced today it will host a conference call on Monday, June 9, 2014 at 5:00 p.
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 ...
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it filed its annual report on Form 10-K for the year ended December 31, 2013.
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, and its collaborators reported today that it has discovered a new method to generate a potent and replenishable...
Advanced Cell Technology (ACTC) today announced that Edward Myles, Interim President, CFO & EVP of Corporate Development, will present at the 2 nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014...
Advanced Cell Technology (OTC:ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position, effective immediately.
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Eddy Anglade, M.
Advanced Cell Technology, Inc. (“ACT”; OTC:ACTC or the “Company”), a leader in the field of regenerative medicine, announced today third quarter financial results for the period ended September 30,...
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it will release its third quarter financial results for the period ended ...
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.
Advanced Cell Technology, Inc. (“ACT”)(OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will webcast its Annual Shareholders’ Meeting to be held on Tuesday, October 22nd...
Advanced Cell Technology, Inc. (“ACT”; OTCQB:ACTC), a leader in the field of regenerative medicine, today announced that Chairman and CEO Gary Rabin will present a corporate overview at the 2013 Aegis...
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that the company’s Chief Scientific Officer, Robert Lanza, MD, has been nominated to receive the ...
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has filed an Investigational New Animal Drug (INAD) application with the Food and Drug...
Advanced Cell Technology, Inc. (“ACT”; OTCQB: ACTC), a leader in the field of regenerative medicine, announced that it has filed preliminary proxy materials with the Securities and Exchange Commission...
Advanced Cell Technology, Inc. (“ACT”; OTCQB: ACTC), a leader in the field of regenerative medicine, announced today second quarter financial results for the period ended June 30, 2013.
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will release its second quarter financial results for the period ended June 30,...
Advanced Cell Technology, Inc. (“ACT”) (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts...
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company’s three ...
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chief scientific officer Robert Lanza, M.
